Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
1+ week, 5+ day ago (199+ words) U.S. Phase III Trial Expands Clinical Investigation of Stem Cell Therapy for Knee Cartilage Defects “Treating the first participant in this trial is a milestone moment, not just for the science but for the osteoarthritis patients I see every day with…...
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
3+ week, 4+ day ago (824+ words) Together, these EAN presentations highlight Lundbeck’s dual focus in migraine: optimizing the use of current preventive treatment options while advancing future therapeutic approaches for people who continue to experience substantial disease burden. “The presentation advances the evolving scientific understanding of…...
The Original Back Hero Posture Corrector by Black N Spine: A Practical Step Toward Better Posture
8+ mon, 2+ week ago (134+ words) Back N Spine introduces the Original Back Hero Posture Corrector, combining ergonomic support and wearability to promote improved alignment and comfort. With a strong focus on spinal health, the company positions this product as part of its broader mission to…...
World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis
8+ mon, 4+ week ago (186+ words) IFPA urges recognition of the close link between psoriasis and mental health — and action to prevent its devastating ripple effects. STOCKHOLM, Oct. 24, 2025 /PRNewswire/ — Every year on October 29, the global community marks World Psoriasis Day, raising awareness and standing in solidarity…...
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
10+ mon, 2+ week ago (897+ words) Biotechnology, Clinical Study, GlobeNewswire, Health, Product / Services Announcement | SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) â Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization…...
Various measures lead to fewer new Chikungunya cases in south China
11+ mon, 1+ week ago (224+ words) New cases of Chikungunya fever in Foshan, a city in south China’s Guangdong Province, have continued to decline thanks to a series of targeted prevention measures, municipal authorities said on Saturday. For the past five days, the city has recorded…...
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
11+ mon, 2+ week ago (307+ words) Preventative treatment can help reduce the frequency of migraine attacks, helping children and adolescents to better manage the condition day-to-day. AJOVY is administered once a month and available for in-office or at home use, offering a treatment option that is…...